Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease

The real-world effectiveness and safety of upadacitinib in Crohn’s disease were assessed in a multicenter retrospective study involving 9 tertiary inflammatory bowel disease (IBD) centers across North America. This study provided insights into the use of upadacitinib in routine clinical practice, focusing on a large cohort of patients with moderate-to-severe Crohn’s disease who were often refractory to prior treatments. Below is a detailed summary of the findings:

Study Overview

• Patient Population: The study included 334 adults with active Crohn’s disease, most of whom had a long disease duration and significant prior exposure to advanced therapies, including biologics or small molecules.
• Treatment Protocol: Upadacitinib, an oral JAK1 inhibitor, was administered as 45 mg daily for induction, followed by 30 mg daily for maintenance therapy in the majority of patients.

---

Effectiveness Outcomes

1. Clinical Remission:

• At 12 Weeks: Over half of the patients achieved clinical remission by the end of the induction period.
• At 6 Months: Clinical remission rates were maintained or improved in patients who continued on treatment, demonstrating sustained effectiveness.

2. Endoscopic Healing:

• Endoscopic remission, reflecting meaningful mucosal healing, was achieved in more than 40% of evaluated patients at 6 months.

3. Therapy-Naïve Patients:

• Patients who were naïve to advanced therapies (biologics or small molecules) had the highest rates of clinical and endoscopic remission, suggesting upadacitinib may be particularly effective in this subgroup.

4. Refractory Patients:

• Even in patients with prior exposure to multiple biologics or small molecules, upadacitinib demonstrated effectiveness, underscoring its utility in refractory cases.

5. Impact of Disease Duration:

• Longer disease duration was associated with lower odds of achieving remission, indicating that earlier intervention may yield better outcomes.

6. Predictors of Response:

• Negative Predictor: Higher body mass index (BMI) independently reduced the likelihood of achieving clinical remission.
• Positive Predictor: Higher baseline albumin levels were associated with better clinical outcomes.

7. Disease Location:

• Short-term remission rates were comparable between patients with ileal-dominant and colon-dominant Crohn’s disease.

8. Biomarker and Imaging Improvement:

• Significant reductions in C-reactive protein (CRP) levels were observed, indicating biological anti-inflammatory effects.
• Radiographic imaging showed improvement or resolution of inflammation in the majority of assessed patients.

9. Histologic Outcomes:

• Histologic remission was achieved in a smaller subset of patients, reflecting stringent criteria and limited biopsy data.

10. Steroid-Sparing Effect:

• Most patients who achieved remission were able to discontinue corticosteroids by follow-up, highlighting the steroid-sparing potential of upadacitinib.

---

Safety Profile

1. Adverse Events:

• Adverse events were reported in a minority of patients, and no new safety signals were identified.
• The safety profile was consistent with prior clinical trials.

2. Serious Adverse Events:

• Serious adverse events, including venous thromboembolism, were infrequent, suggesting an acceptable safety profile for upadacitinib in this population.

---

Clinical Implications

• Effectiveness in Real-World Settings: The study supports upadacitinib as an effective treatment option for moderate-to-severe Crohn’s disease, including in patients with refractory disease or prior treatment failures.
• Best Results in Therapy-Naïve Patients: Upadacitinib may offer the greatest benefit when used earlier in the treatment course, particularly in therapy-naïve patients.
• Personalized Treatment: Factors such as BMI, albumin levels, and disease duration should be considered when predicting treatment response and tailoring therapy.

---

Conclusion

Upadacitinib demonstrated robust real-world effectiveness and an acceptable safety profile in the treatment of moderate-to-severe Crohn’s disease. It was effective across various patient subgroups, including those with refractory disease, and showed meaningful clinical, endoscopic, and biomarker improvements. These findings support its role as a valuable therapeutic option in managing Crohn’s disease in routine clinical practice.